Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H13ClF4N2O3 |
| Molecular Weight | 416.754 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@](O)(COC1=CC=C(Cl)C(F)=C1)C(=O)NC2=CC=C(C#N)C(=C2)C(F)(F)F
InChI
InChIKey=SSFVOEAXHZGTRJ-KRWDZBQOSA-N
InChI=1S/C18H13ClF4N2O3/c1-17(27,9-28-12-4-5-14(19)15(20)7-12)16(26)25-11-3-2-10(8-24)13(6-11)18(21,22)23/h2-7,27H,9H2,1H3,(H,25,26)/t17-/m0/s1
| Molecular Formula | C18H13ClF4N2O3 |
| Molecular Weight | 416.754 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:14:53 GMT 2023
by
admin
on
Sat Dec 16 09:14:53 GMT 2023
|
| Record UNII |
XDK89456WM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-S-23
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1010396-29-8
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY | |||
|
DB07419
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY | |||
|
24892822
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY | |||
|
DTXSID701045802
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY | |||
|
S-23 (drug)
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY | S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment. | ||
|
XDK89456WM
Created by
admin on Sat Dec 16 09:14:53 GMT 2023 , Edited by admin on Sat Dec 16 09:14:53 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
